ArmeniaTuberculosis profile
Population  2016 2.9 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.062 (0.037–0.094) 2.1 (1.3–3.2)
Mortality (HIV+TB only) 0.015 (0.011–0.021) 0.52 (0.36–0.7)
Incidence  (includes HIV+TB) 1.3 (0.98–1.6) 44 (34–56)
Incidence (HIV+TB only) 0.074 (0.048–0.11) 2.5 (1.6–3.6)
Incidence (MDR/RR-TB)** 0.28 (0.21–0.35) 9.6 (7.2–12)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.065 (0.049–0.081) 0.27 (0.2–0.33) 0.33 (0.25–0.41)
Males 0.073 (0.055–0.092) 0.88 (0.66–1.1) 0.95 (0.71–1.2)
Total 0.14 (0.1–0.17) 1.1 (0.86–1.4) 1.3 (0.98–1.6)
TB case notifications, 2016  
Total cases notified 1 080
Total new and relapse 1 027
          - % tested with rapid diagnostics at time of diagnosis 6%
          - % with known HIV status 100%
          - % pulmonary 81%
          - % bacteriologically confirmed among pulmonary 53%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.06 (0.04–0.09)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 57 6%
          - on antiretroviral therapy 57 100%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  180
(160–210)
Estimated % of TB cases with MDR/RR-TB 11% (8–14) 47% (40–55)  
% notified tested for rifampicin resistance 21% 26% 244
MDR/RR-TB cases tested for resistance to second-line drugs   113
Laboratory-confirmed cases MDR/RR-TB: 128, XDR-TB: 29
Patients started on treatment **** MDR/RR-TB: 131, XDR-TB: 29
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 79% 910
Previously treated cases, excluding relapse, registered in 2015 77% 13
HIV-positive TB cases registered in 2015 65% 72
MDR/RR-TB cases started on second-line treatment in 2014 58% 118
XDR-TB cases started on second-line treatment in 2014 40% 10
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 23%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 7
Funding source: 42% domestic, 58% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-15 Data: www.who.int/tb/data